Exosomal microRNA in plasma as a non‑invasive biomarker for the recurrence of non‑small cell lung cancer

Dejima,Hitoshi; Iinuma,Hisae; Kanaoka,Rie; Matsutani,Noriyuki; Kawamura,Masafumi

doi:10.3892/ol.2017.5569

Exosomal microRNA in plasma as a non‑invasive biomarker for the recurrence of non‑small cell lung cancer

Authors:
- Hitoshi Dejima
- Hisae Iinuma
- Rie Kanaoka
- Noriyuki Matsutani
- Masafumi Kawamura
View Affiliations

Affiliations: Department of Surgery, Teikyo University School of Medicine, Tokyo 173‑0003, Japan
Published online on: January 4, 2017 https://doi.org/10.3892/ol.2017.5569
Pages: 1256-1263

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Predictive biomarkers for the recurrence of non‑small cell lung cancer (NSCLC) in patients who have received curative resection are important for cancer treatment. The functional microRNAs (miRNAs/miRs) in the exosomes of plasma and serum samples are of interest as stable and non‑invasive biomarkers for recurrence in cancer patients. The aim of the present study was to clarify the usefulness of plasma exosomal miRNAs as biomarkers for the prediction of recurrence in NSCLC following curative resection. First, microarray‑based expression profiling of miRNAs derived from exosomes in the plasma of 6 patients was employed to identify a biomarker that distinguishes between patients with and without NSCLC recurrence. In the miRNA microarray analyses, the exosomal miR‑21 and miR‑4257 levels of the NSCLC patients showed marked upregulation in those individuals with recurrence compared with those without recurrence and healthy individuals. These two miRNAs were thus selected as recurrence‑specific biomarkers and their potential was evaluated in a separate cohort of 195 NSCLC patients. In comparison to the levels in 30 healthy individuals, exosomal miR‑21 and miR‑4257 levels showed a significant increase in the NSCLC patients (P<0.01). When evaluating the clinicopathological significance of these miRNAs, exosomal miR‑21 showed a significant association with tumor size and tumor‑node‑metastasis (TNM) stage (P<0.05). Exosomal miR‑4257 showed a significant association with histological type, lymphatic invasion and TNM stage (P<0.05). The disease‑free survival (DFS) rates of high exosomal miR‑21 patients were significantly worse than those of low exosomal miR‑21 patients (P<0.05), and the DFS rates of patients with high exosomal miR‑4257 levels were significantly worse than those with low exosomal miR‑4257 levels (P<0.01). In the Cox multivariate analysis, plasma exosomal miR‑21 and miR‑4257 expression showed a significance association with DFS (P<0.05). These results suggest that plasma exosomal miR‑21 and mir‑4257 expression has potential as a predictive biomarker for recurrence in NSCLC patients who have received curative resection.

View Figures

View References

1	Wakao F, Nishimoto H, Katanoda K, et al: Cancer Statistics in Japan 2015Editorial Board of the Cancer Statistics in Japan (ed.). Foundation for Promotion of Cancer Research c/o National Cancer Center; Tokyo: pp. 1–129. 2016
2	Maeda T, Ueda H, Tabata M, Kiura K, Shibayama T, Gemba K, Takigawa N, Hiraki A, Katayama H and Harada M: Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Cin Oncol. 30:534–541. 2000. View Article : Google Scholar
3	Del Vescovo V, Grasso M, Barbareschi M and Denti MA: MicroRNAs as lung cancer biomarkers. World J Clin Oncol. 5:604–620. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang QZ, Xu W, Habib N and Xu R: Potencial uses of microRNA in lung cancer diagnosis, prognosis, and theray. Curr Cnacer Drug Targets. 9:572–594. 2009. View Article : Google Scholar
5	Deng D, Liu Z and Du Y: Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomatkers. Adv Genet. 71:125–176. 2010.PubMed/NCBI
6	Grady WM and Tewai M: The next thing in prognostic molecular markers: MicroRNA signatures of cancer. Gut. 59:706–708. 2010. View Article : Google Scholar : PubMed/NCBI
7	Chen X, Ba Y, Ma I, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characteruzation of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
8	Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED and Harris CC: Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 130:1378–1386. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ulivi P and Zoli W: miRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules. 19:8220–8237. 2014. View Article : Google Scholar : PubMed/NCBI
10	Powrózek T, Krawczyk P, Kowalski DM, Winiarczyk K, Olszyna-Serementa M and Milanowski J: Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. Transl Res. 166:315–323. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE and Wang MX: Plasma microRNAs as novel biomarker for early detection of lung cancer. Int J Clin Exp Pathol. 4:575–586. 2011.PubMed/NCBI
12	Kowal J, Tkach M and Théry C: Biogenesis and secretion of exosome. Curr Opin Cell Biol. 29:116–125. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ge Q, Zhou Y, Lu J, Bai Y, Xie X and Lu Z: miRNA in plasma exosome is stable under different storage conditions. Molecules. 19:1567–1575. 2014. View Article : Google Scholar
14	Palma J, Yaddannapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML and Duelli DM: MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40:9125–9138. 2012. View Article : Google Scholar : PubMed/NCBI
15	Simons M and Raposo G: Exosomes-vesicular carriers for intercelluar communication. Curr Opin Cell Biol. 21:575–581. 2009. View Article : Google Scholar : PubMed/NCBI
16	Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18:883–891. 2012. View Article : Google Scholar : PubMed/NCBI
17	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanisms of genetic exchange between cells. Nat cell Bio. 9:654–659. 2007. View Article : Google Scholar
18	Hannafon BN and Ding WQ: Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 14:14240–14269. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M and Baba H: Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcnoma. Cancer. 119:1159–1167. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H and Sonoda H: Circulatung exosomal microRNAs as biomarkers of colon cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
21	Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K, et al: Idenification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 112:532–538. 2015. View Article : Google Scholar : PubMed/NCBI
22	Travis WD, Brambilla E, Buke AP, Marx A and Nicholson AG: WHO classification of tumors of the lung, pleura, thymus and heartBosman FT, Jaffe ES, Lakhani SR and Ohgaki H: International Agency for Research on Cancer; France: pp. pp1–pp412. 2015
23	General rule for clinical and pathological record of lung cancer, . The Japan Lung Cancer Society (ed.). Kenehara Co. Ltd; Tokyo: pp. pp1–pp213. 2014
24	Guidelines 2014 for treatment of lung cancer by EBM, . Japan Lung Cancer Society (ed.). Kenehara Co. Ltd; Tokyo: pp. pp1–pp201. 2014
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Li P, Ju H, Pesta M, Kulda V, Jin W, Cai M, Liu C, Wu H, Xu J, et al: Diagnostic and prognostic value of microRNA-21 in colorectal cancer: An original study and individual participant data meta-analysis. Cancer Epidemiol Biomarkers Prev. 23:2783–2792. 2014. View Article : Google Scholar : PubMed/NCBI
27	Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM and De W: Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 104:847–851. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sanfiorenzo C, Iiie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P and Hofman P: Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One. 8:e545962013. View Article : Google Scholar : PubMed/NCBI
29	Gao F, Chang J, Wang H and Ahang G: Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol Rep. 31:351–357. 2014.PubMed/NCBI
30	Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
31	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
32	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
33	Motoyama K, Onoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K and Mori M: Clinicopathological and prognostic significance of pdcd4 and microRNA-21 in human gastric cancer. Int J Oncol. 36:1089–1095. 2010.PubMed/NCBI
34	Horiuchi A, Iinuma H, Akahane T, Shimada R and Watanabe T: Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients. Oncol Rep. 27:1384–1392. 2012.PubMed/NCBI
35	Bai R, Shi Z, Zhang JW, Li D, Zhu YL and Zheng S: ST13, a proliferation regulator, inhibits growth and migration of colorectal cancer cell lines. J Zhejiang Univ Sci B. 13:884–893. 2012. View Article : Google Scholar : PubMed/NCBI